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Abstract
The membrane-proximal external region (MPER) of the HIV-1 gp41 consists of epitopes for the broadly cross-neutralizing
monoclonal antibodies 2F5 and 4E10. However, antigens containing the linear sequence of these epitopes are unable to
elicit potent and broad neutralizing antibody responses in vaccinated hosts, possibly because of inappropriate
conformation of these epitopes. Here we designed a recombinant antigen, designated NCM, which comprises the N- and
C-terminal heptad repeats that can form a six-helix bundle (6HB) core and the MPER domain of gp41. Two mutations
(T569A and I675V) previously reported to expose the neutralization epitopes were introduced into NCM to generate
mutants named NCM(TA), NCM(IV), and NCM(TAIV). Our results showed that NCM and its mutants could react with
antibodies specific for 6HB and MPER of gp41, suggesting that these antigens are in the form of a trimer of heterodimer
(i.e., 6HB) with three exposed MPER tails. Antigen with double mutations, NCM(TAIV), elicited much stronger antibody
response in rabbits than immunogens with single mutation, NCM(TA) and NCM(IV), or no mutation, NCM. The purified
MPER-specific antibodies induced by NCM(TAIV) exhibited broad neutralizing activity, while the purified 6HB-specific
antibodies showed no detectable neutralizing activity. Our recombinant antigen design supported by an investigation of
its underlying molecular mechanisms provides a strong scientific platform for the discovery of a gp41 MPER-based AIDS
vaccine.
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Introduction
As the acquired immunodeficiency syndrome (AIDS) pandemic
continues to expand globally, the search for a preventive vaccine is
an absolute priority in combating its causative agent, human
immunodeficiency virus type 1 (HIV-1). Stimulating the humoral
arms of the host immune response and designing immunogens
capable of eliciting broadly neutralizing antibodies (BNAbs) is a
paramount goal for AIDS vaccine development [1]. However, the
ability of HIV-1 to evade host immune defenses, along with
substantial genetic variation, has posed major stumbling blocks to
thwart this effort [2].
Clinical studies indicate that the antisera of some HIV-1-
infected patients exhibit broad and potent neutralizing activity
[3,4]. Nevertheless, only a handful of BNAbs have been identified
to date. Three of those, monoclonal antibodies (mAbs) 2F5, 4E10
and Z13, target the adjacent linear epitopes located in the
membrane-proximal external region (MPER) of gp41 [5,6],
which plays a crucial role in membrane fusion and viral entry.
The gp41 ectodomain contains the N- and C-terminal heptad
repeats (NHR and CHR), which can interact with each other to
form a six-helix bundle (6HB, also known as a trimer of
heterodimers), a fusion core conformation of gp41 (Fig. 1A). The
mAb 2F5 recognizes a core epitope of six amino acids ELDKWA
(aa 662–667) in the MPER [5]. The core binding motif, DKW, is
in an extended b-turn conformation in complex with 2F5
antibody as shown by crystallographic study [7]. The 4E10
epitope comprises the linear sequence NWFNIT (aa 671–676)
with several crucial Trp residues adjacent to the core motif [6,8]
and adopts a helical conformation [9]. The residue F673 swings
180u from membrane interior to the antibody binding pocket
[10]. Before the recent identification of BNAbs PG9, PG16,
VRC01 and VRC02 [11,12], 2F5 had been the most potent
neutralizing antibody, whereas 4E10 was able to neutralize the
broadest range of different viral isolates [13,14]. The relatively
conserved and linear property of these neutralizing epitopes
makes MPER one of the most attractive targets for development
of an HIV-1 vaccine.
Unfortunately, in contrast to the loop region of gp41, the
MPER is weakly immunogenic [15]. A number of immunization
studies demonstrated that the MPER-containing recombinant
proteins, proteins expressed on Virus-Like Particles (VLPs) and
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antibodies [16,17,18]. Thus, designing immunogens that produce
high titers of MPER-specific antibodies is the prerequisite for an
MPER-based vaccine. Blish et al. have shown that introduction of
two mutations (T569A and I675V) into gp41 results in significantly
enhanced exposure of the conserved neutralization epitopes in
MPER and renders the HIV-1 mutants 360- and 180-fold more
susceptible to 2F5 and 4E10, respectively [19].
Figure 1. Immunogen design and protein purification. (A) Schematic representation of gp41 and NCMs. The gp41 molecule consists of fusion
peptide (FP), N-terminal heptad repeat (NHR), loop (immunodominant) region, C-terminal heptad repeat (CHR), membrane-proximal external region
(MPER), and cytoplasm tail (CT). (B) The amino acid sequences of NCMs. The sequence of N36 and C34 are in brown and blue, respectively. The
epitopes for 2F5 (ELDKWA) and 4E10 (NWFDIT) are highlighted in red and green, respectively. The mutations of T569A and I675V are in boldface. (C)
NCMs may form 6HB with exposed MPER tails. The epitopes for 2F5 and 4E10 are in red and green, respectively. (D) SDS-PAGE analysis of purified
NCMs. The estimated molecular weight of NCMs is 11.8 kD. (E) Chemical cross-linking assay of NCM. NCM(IV), NCM(TA) and NCM(TAIV) showed similar
results (data not shown).
doi:10.1371/journal.pone.0018233.g001
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mutations into an MPER-based HIV-1 vaccine candidate might
increase its immunogenicity to elicit stronger MPER-specific
antibodies with broad neutralizing activity. In the present study,
we constructed and expressed a recombinant immunogen
consisting of the N- and C-terminal heptad repeats that can form
a six-helix bundle (6HB) and the MPER region of gp41. Two
mutations (T569A and I675V) previously reported to expose the
neutralization epitopes were introduced into NCM to generate
mutants named NCM(TA), NCM(IV) and NCM(TAIV). As
expected, relatively high titers of the MPER-specific antibodies
were induced by NCM(TAIV). These antibodies exhibited broad
and potent neutralizing activity.
Materials and Methods
Peptides, cells and viruses
All peptides, including MPER (aa 659–683), MPER(IV) (MPER
peptide with I675V mutation), M1 (aa 645–663), M2 (aa 638–
672), M3 (aa 662–676) and M4 (aa 671–683), were synthesized by
SBS Genetech, Beijing, China, with purity .90%.
3T3 cells stably transduced with MLV MX-CD4 and MX-
CXCR4 vectors (3T3.T4.CXCR4) were cultured in Dulbecco’s
modified Eagle medium (DMEM) with 10% fetal bovine serum
(FBS) (Invitrogen, Carlsbad, CA). CHO cells stably transfected
with either the HIV-1 HXB2 Env expressing vector pEE14
(CHO-WT) or control pEE14 vector (CHO-EE) were cultured in
Glutamine-deficient minimal essential medium (GMEM) con-
taining 400 mM Methionine sulfoximine (Sigma, St. Louis, MO).
MT-2 and TZM-bl cells; plasmids, including pNL4-3.LucR
2E
2,
Env- expressing plasmid pHXB2 and pJRFL; viruses, including
HIV-1 strains IIIB, Bal, and primary HIV-1 isolates, were
obtained from the NIH AIDS Research and Reference Reagent
Program. GFP-transduced human osteosarcoma cells (Ghost)
target cells which express CD4 and both coreceptors CCR5 and
CXCR4 were kindly provided by Dr. Linqi Zhang at Tsinghua
University.
Protein expression and purification
NCM is composed of the NHR (aa 546–581) followed by an 8
amino acids linker (GGGKLGGG), CHR (aa 628–658) and
MPER (aa 659–683). The cDNA was amplified from pcDNA3.1-
gp160 (HXB2) plasmid and cloned into pGEX-6p-1 vector (GE
Healthcare, Sweden). Three mutations were constructed by a
standard point mutation method by PCR. The plasmids were
transformed into E. coli strain Rosetta. The proteins were induced at
16uC with 1 mM IPTG for 12 hours. Purification of the proteins
followed a standard procedure with glutathione Sepharose 4B Fast
flow beads (GE Healthcare, Sweden). The GST-fusion proteins on
beads were cut by PreScission protease (GE Healthcare, Sweden)
at 4uC overnight in PPase buffer (150 mM NaCl, 100 mM Tris,
1 mM EDTA, 1 mM DDT). The beads were washed with 1 mM
glutathione in PBS to remove GST (NCM bound tightly to beads).
The NCMs were collected by washing beads with 6 M guanidine.
All proteins were purified to homogeneity by Vydac C4 Reversed-
Phase Columns (Grace, MA), lyophilized and stored at 220uC.
NCMs were dissolved by PBS buffer with 0.1% triton X-100 for
hydrophobic character of MPER. Expression and purification of
six-helix bundle (6HB) protein composed of NHR and CHR of
gp41, N36(L8)C34, was described previously [20]. Protein
concentrations were quantified with bicinchoninic acid (BCA)
assay.
Chemical cross-linking and Western blot analysis
Cross-linking study was performed as described by Mische et al
[21]. Briefly, NCMs were treated with 0, 0.1, 0.4 and 4 mM
glutaraldehyde (GA),respectively,for1.5 hat roomtemperatureand
were separated by SDS-PAGE. The protein bands in the gels were
transferred into a PVDF membrane (Millipore) and analyzed with
Western blot using the mAb NC-1 [22] as the primary antibody.
Table 1. The immunogenicity of NCMs after the third immunization.
Group Immunogen Rabbit Titers of antibodies specific for
No Immunogen MPER peptide MPER (IV) peptide
I NCM 1 1:4610
5 ,1:400 ,1:400
21 : 1 610
5 1:1600 1:800
31 : 1 610
5 ,1:400 ,1:400
Geometric mean titer 1:1.6610
5 1:635 1:504
II NCM(IV) 4 1:1610
5 1:800 1:800
51 : 4 610
5 1:3200 1:3200
61 : 4 610
5 1:400 1:400
Geometric mean titer 1:2.5610
5 1:1008 1:1008
III NCM(TA) 7 1:1610
5 1:1600 1:800
81 : 1 610
5 ,1:400 ,1:400
91 : 4 610
5 1:3200 1:3200
Geometric mean titer 1:1.6610
5 1:1270 1:1008






Geometric mean titer 1:4610
5 1:20319 1:16127
Note: ‘‘,1:400’’ was treated as 1:400 when the Geometric mean titer was calculated.
doi:10.1371/journal.pone.0018233.t001
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The NCMs were coated onto the microtiter plates (0.25 mg/
well, pH 9.6, 0.1 M NaHCO3)a t4 uC overnight and blocked by
0.3% gelatin (in PBS) for 1 h. Then the primary antibodies 2F5,
4E10 (Polymun, Austria) or NC-1 were added and incubated for
1 h. Thereafter, the peroxidase-conjugated anti-human (Sigma,
MO) or anti-mouse immunoglobulin antibodies (Dako, Denmark)
were added, and 1 h incubation was performed. The freshly
prepared substrate solution (10 mg OPD in 10 ml, pH 5.0, 0.1 M
citrate buffer, and 18 mlH 2O2) was then added to each well. The
reaction was stopped by 2 M H2SO4 10 minutes later, and the
absorbance at 490 nm (A490) was read by a Bio-Rad Model 680
(Hercules, CA).
Surface plasmon resonance (SPR) assay
A BIAcore X instrument was used in SPR binding assays. The
SPR experiment to investigate the binding of 2F5 to NCMs on
membrane was performed as previously described [23]. Briefly,
liposomes of a mixture of POPC/Chol/SM (1:1:1) were captured
onto sensor chip L1 surface. After washing away the loosely
bound liposomes by a NaOH pulse, 45 ml0 . 6 mMN C Mo r
mutants were injected. Then the capture levels were measured
after a 400 s delay. 0.01% Triton X-100 in buffer, which was
crucial for NCM solubility, was confirmed not to cause large
baseline changes in this study by buffer-only injections over
membrane surface (changed 51616 RU, 0.5% of capture level of
liposomes to chip surface). Injections of 2F5 (50–200 nM, 60 s) or
4E10 (100–300 nM, 96 s) were taken subsequently, followed by
uniform dissociation time (600 s). The data were analyzed by
BIAevaluation 3.1 in 1:1 binding with drifting baseline model,
which had lower x
2 values than those of a two-step binding
model.
Figure 2. Binding of anti-gp41 mAbs to NCMs. Binding of human
mAb 2F5 (A), 4E10 (B) and mouse mAb NC-1 (C) to NCMs, as determined
by ELISA.
doi:10.1371/journal.pone.0018233.g002
Figure 3. Binding of antisera to MPER or MPER(IV) peptide.
Two-fold serially diluted rabbit sera were added to peptide MPER- (A) or
MPER(IV) (B) -coated 96-well plates. Each datum is the average of A490
value of three rabbits in the same group.
doi:10.1371/journal.pone.0018233.g003
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Twelve female New Zealand rabbits enrolled for the immuni-
zation were randomly allotted to four different groups, three for
each group (Table 1). The study of animals was carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health and Tsinghua University. The protocol was approved by
the Committee on the Ethics of Animal Experiments of Tsinghua
University (Permit Number: 2010-ChenYH-A2). All efforts were
made to minimize suffering. The rabbits were immunized 3 times
with 50 mg immunogen at day 0, 14 and 28 by subcutaneous
injections. Complete Freund’s adjuvant was used for the priming
and incomplete Freund’s adjuvant for the next two boosts. Pre-
immunization blood samples were collected one day before the
primary immunization. The terminal bleeding was done on day
35. Sera were stored at 220uC.
The immunogenicity of NCMs and MPER in the individual
immunogens was characterized by indirect ELISA. The synthetic
peptide MPER or NCMs were coated onto the microtiter plates
(0.25 mg/well). Sera were serially diluted and added into wells.
The peroxidase-conjugated anti-rabbit immunoglobulin antibod-
ies (Dako, Denmark) served as secondary antibodies. The OPD
substrate was used and quenched by 2 M H2SO4 10 minutes later.
Titers of the antigen-specific antibodies were expressed as the
highest dilution of serum that reacted with the coating antigens
(the average values of A490 nm $0.2).
Purification of MPER- and 6HB-specific antibodies from
rabbit antisera
Two mg of MPER peptide (aa 659–683) or a recombinant 6HB
mimetic, N36(L8)C34 were coupled to NHS-activated Sepharose
4 Fast Flow beads (GE Healthcare, Sweden) for purification of
MPER- or 6HB-specific antibodies according to the manufactur-
er’s instruction. Briefly, sera were diluted four times with PBS and
passed through the affinity column. The column was washed with
20 ml PBS to remove nonspecific antibodies. The MPER- or
6HB-specific antibodies were eluted with low pH elution buffer
(pH 2.5, 0.1 M Glycine). The purified antibodies were then
Table 2. Neutralizing activity of anti-MPER antibodies against Env-mediated syncytium-formation and infection by HIV-1
pseudoviruses, laboratory-adapted and primary strains.
HIV-1 isolates Subtypes Coreceptor tropism IC50 (mg/ml)
Anti-6HB IgG Anti-MPER IgG 2F5 4E10
Env-mediated syncytium-formation .150 8.763.8 6.762.9 21.0612.4
HIV-1 pseudoviruses
HXB2 B X4 .150 15.263.3 1.060.1 0.660.3
JRFL B R5 .150 23.866.4 1.460.2 3.962.1
Laboratory-adapted HIV-1 strains
IIIB B X4 .150 64.6616.8 13.263.7 8.361.6
Bal B R5 .150 79.662.6 16.165.1 9.261.1
Primary HIV-1 isolates
94UG103 A X4R5 .150 .150 27.164.3 41.868.3
92US657 B R5 .150 142.1627.7 10.262.9 7.563.5
93MW959 C R5 .150 140.5618.9 37.565.6 7.161.7
RU570 G R5 .150 .150 17.268.2 25.167.6
92TH009 A/E R5 .150 98.2611.5 6.361.1 3.560.9
doi:10.1371/journal.pone.0018233.t002
Figure 4. Inhibitory activity of antibodies on cell-to-cell
transmission of HIV-1. Anti-MPER IgGs and ani-6HB IgGs were
tested for inhibition of HIV-1 IIIB and Bal transmission from PBMCs to
CEMx174 5.25M7 cells.
doi:10.1371/journal.pone.0018233.g004
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centrifugal filter device (Millipore, MA). The antibody concentra-
tions were quantified by measuring absorbance at 280 nm and
stored at 4uC until use.
Assay for HIV-1 Env-mediated syncytium-formation
The assay for detecting the HIV-1 Env-mediated syncytium-
formation was performed as previously described [24]. Briefly,
(3T3.T4.CXCR4) cells (5610
4) were plated in 48-well plates,
followed by an overnight incubation at 37uC and washed with
GMEM-S medium. Then, 3610
4 effector (CHO-WT) cells pre-
stimulated with 6.5 mM sodium butyrate for about 20 h were
added in the presence of an antibody at a serial 2-fold dilution.
After a co-culture at 37uC for 24 h, the syncytia, defined as giant
cells with diameters more than four times larger than those of
single cells, were counted under a microscope. The percentage
inhibition of syncytium-formation was calculated as previously
described [24], and the concentration for 50% inhibition (IC50)
was calculated using the CalcuSyn software [25].
HIV-1 neutralization assays
The neutralizing activity of antibodies was first determined
using a single-cycle pseudovirus infection assay as previously
described [26]. In brief, pseudoviruses were generated by transient
transfection of HEK 293T cells with pNL4-3.LucR
2E
2 and an
Env-expressing plasmid pHXB2 or pJRFL. The mixture of a
pseudovirus at a concentration yielding 50,000–100,000 relative
luminescence units (RLU) and a serial 2-fold dilution of an
antibody (final concentration 4.7–150 mg/ml) was added to
DMEM medium in wells of 96-well plates to reach a total volume
of 100 ml. After incubation at 37uC for 1 h, 100 ml of Ghost cells
(1610
5/ml) were added and cultured at 37uCi n5 %C O 2 for 48 h.
RLUs were determined with a luciferase kit (Promega, Madison,
WI) and luminometer (Ultra 386, Tecan, Durham, NC) following
the instructions of the manufacturers.
The neutralizing activity of antibodies on infection by HIV-1
strain IIIB was determined as previously described [27]. Briefly,
MT-2 cells (1610
4/well) were infected with HIV-1 IIIB at 100
TCID50 (50% tissue culture infective dose) in the absence or
presence of 2-fold serially diluted antibodies in 200 ml RPMI
medium 1640 containing 10% FBS overnight. The supernatants
were removed, and fresh medium was added the next day. On the
fourth day post-infection, 100 ml of culture supernatants from each
well were collected and mixed with equal volumes of 5% Triton
X-100 for testing p24 antigen using an in-house ELISA previously
described [27].
The neutralizing activity of antibodies on infection by HIV-1
R5 strain Bal and primary isolates was performed as described
before [28]. Briefly, 100 ml of TZM-bl cells (1610
5/ml) were pre-
Figure 5. Immunoinformatic analysis of physicochemical properties of MPER. (A) Hydrophilicity, (B) Flexibility, (C) Turn propensity and (D)
Antigenic propensity. All analyses were performed by BcePred server.
doi:10.1371/journal.pone.0018233.g005
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100 TCID50 in the absence or presence of a serially diluted
antibody. After co-culture at 37uC for 48 h, the cells were
harvested and lysed by the lysing reagent in the luciferase assay kit.
The RLUs were determined with luciferase kit and luminometer
as described above. The percent of inhibition and the IC50 values
were calculated with the CalcuSyn software as described above.
Assessment of inhibition of antibodies on HIV-1
transmission from PBMCs to CEM6174 5.25M7 cells
Inhibitory activity of antibodies on HIV-1 transmission was
assessed as previously described [29]. In brief, PHA/IL-2-
stimulated PBMCs were infected by HIV-1 IIIB and Bal (a
multiplicity of infection of 0.01) for 7 days and washed with culture
medium for 3 times to remove free viral particles. Subsequently,
50 ml of HIV-1- infected PBMCs (1610
6/ml) were incubated with
50 ml of antibodies at 37uC for 30 min. Then, 100 ml of CEMx174
5.25M7 cells (5610
6/ml) were added and co-cultured at 37uC for
72 h. The cells were collected and lysed for analysis of luciferase
activity, using a luciferase assay kit (Promega) as described above.
Results
Expression, purification, and characterization of NCM and
its mutants
NCMs, including non-mutated NCM and three mutants,
NCM(TA), NCM(IV) and NCM(TAIV) (Fig. 1A), were composed
of NHR, CHR and MPER region derived from gp41 of a clade B
strain HXB2. NCMs were expressed in E. coli and purified by
HPLC with C4 preparative column. Purified NCMs appeared as a
single band on SDS-PAGE at ,12 kD (Fig. 1D). Chemical cross-
linking of NCM with increasing concentration of glutaraldehyde
(GA) resulted in the appearance of two new bands at ,24 kD
(dimer) and ,36 kD (trimer) (Fig. 1E). NCMs were further
characterized by ELISA using two MPER-specific neutralizing
mAbs (2F5 and4E10)[5,7,9,13,14]anda6HB-specificmAb(NC-1)
[22]. Similar totheNCMwith wild-type sequence,we found that all
the mutated NCMs could react with both MPER- and 6HB-specific
mAbs in a dose-dependent manner (Fig. 2). These results suggest
that each of these NCMs presents in solution mostly as a trimer of
heterodimer (i.e., 6HBs) with three exposed MPER tails (Fig. 1C).
NCM variant with double mutations, NCM(TAIV), elicited
higher titers of MPER-specific antibody responses in
rabbits than NCM and its variants with single mutation,
NCM(TA) and NCM(IV)
To compare the immunogenicity of the four NCMs, which show
one or two amino acid difference, the rabbit antisera induced by
NCMs were evaluated by testing their binding to two MPER-peptides
(Table 1). Although all rabbits generated high titers of antibodies
against NCMs, the immunogenicity of MPER in different NCMs
varied tremendously. The antiserum induced by NCM(TAIV) showed
much higher titers of MPER-specific antibodies (1:12800–1:25600)
than non-mutated and two other single- mutated forms (Table 1 and
Fig. 3), which indicated that, among the four NCMs, NCM(TAIV)
produced the best induction of MPER-specific antibodies.
MPER-specific antibodies purified from anti-NCM(TAIV)
sera exhibited broad neutralizing activity
To evaluate the anti-viral activity, all antisera were tested in a
pseudovirus assay using Ghost cells which express CD4, CCR5 and
CXCR4. First, a sensitive pseudovirus assay to detect neutralizing
antibodies (NAbs) was performed [26,30]. The antisera to
NCM(TAIV) could neutralize 50% of pseudovirus expressing
HXB2 or JRFL envelope proteins at a dilution of 1:20. On the
other hand, no antisera exhibited 50% neutralization in a TZM-bl
assay using HIV-1 isolate Bal or a p24 assay using isolate IIIB at the
same dilution. The purified MPER-specific antibodies (anti-MPER)
showed significant neutralizing activity to HXB2 and JRFL in a
pseudovirus assay, as well as in an Env-mediated syncytium-
formation, with IC50 values all below 25 mg/ml (Table 2). When
tested in assays using PBMC-derived viruses, MPER-specific
antibodies could neutralize isolates IIIB and BaL and several
primary isolates, including 92US657 (subtype B), 93MW959
(subtype C) and 92TH009 (subtype A/E), with IC50 values below
150 mg/ml, but failed to neutralize primary isolates 94UG103
(subtype A) and RU570 (subtype G) (Table 2). In contrast, no
significant neutralizing activity was shown by the 6HB-specific
antibodies (anti-6HB) in any of the assays. Since cell-to-cell spread of
HIV-1playsan importantroleinHIV-1dissemination[31],anassay
was performed to determine whether MPER-specific antibodies
could inhibit cell-to-cell transmission of HIV-1. In this assay,PBMCs
infected by HIV-1 IIIB or Bal were co-cultured with CEMx174
5.25M7 cells in the presence or absence of MPER-specific
antibodies. As shown in Fig. 4, MPER-specific antibodies, but not
6HB-sepcific antibodies, blocked cell-to-cell transmission of HIV-1
IIIB and Bal strains with IC50 of 56.467.2 and 79.268.1 mg/ml,
respectively, suggesting that the MPER-specific antibodies are
effective in blocking cell-to-cell transmission of HIV-1.
Potential mechanism to explain improved
immunogenicity of NCM(TAIV)
To understand why NCM(TAIV) exhibited higher immunoge-
nicity than NCM, NCM(TA) and NCM(IV), we used an
Figure 6. Exploring binding sites of anti-MPER. (A) Schematic
representation of peptides used for scanning the binding sites of anti-
MPER. (B) Results of anti-MPER binding to peptides in ELISA. MAbs 2F5
and 4E10 were used as control. The concentration of each antibody was
0.2 mg/ml.
doi:10.1371/journal.pone.0018233.g006
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epitopes on MPER based on recurrent neural network [32]. The
results indicated that two epitopes existed in the MPER of gp41,
including ELDKWASLWN and SLWNWFNITN, with scores of
0.69 and 0.50, respectively. These two epitopes actually overlap
the epitopes for the human broad neutralizing mAbs 2F5
(ELDKWA) and 4E10 (NWFNIT), respectively [5,7,9,13,14].
Interestingly, the mutated epitope SLWNWFNVTN (I675V)
exhibited a higher score (0.54) than the non-mutated epitope,
suggesting that this sequence has a higher probability of
functioning as an antibody epitope by this mutation. Subsequently,
we analyzed the physicochemical property changes caused by
mutation I675V with BcePred server [33]. As expected, the I657V
mutation could increase the antigenic propensity of the
NWFNITNW region because of the elevated hydrophilicity,
flexibility and turns (Fig. 5). We could not predict the potential
influence of T569A mutation on the immunogenicity of
NCM(TAIV) using these methods because this residue is far away
from the epitopes in the MPER of gp41.
To further define the binding site(s) of the NCM(TAIV)-induced
antibodies with neutralizing activity, we synthesized 5 peptides,
including MPER and M3 (which contain both 2F5 and 4E10
epitopes), M2 and M4 (containing 2F5 and 4E10 epitopes,
respectively), and M1 (containing neither 2F5 nor 4E10 epitope)
(Fig. 6), and used these peptides to determine the binding
specificity of the purified MPER-specific antibodies with ELISA.
As shown in Fig. 6, mAb 2F5 bound to MPER, M2 and M3
peptides, while mAb 4E10 recognized MPER, M3 and M4
peptides. Similar to 4E10, the MPER-specific antibodies induced
by NCM(TAIV) strongly reacted with MPER, M3 and M4
peptides that contain the NWFNIT-epitope, but showed only
marginal binding activity to M2 peptide containing the
ELDKWA-epitope. These data indicate that the immunogen
NCM(TAIV) has increased immunogenicity to induce antibodies
against the 4E10 epitope.
Surface plasmon resonance (SPR) assay was utilized to evaluate
the kinetics and affinity of mAbs 2F5 and 4E10 for binding to
NCMs immobilized on membranes since membrane was suggest-
ed to be a crucial component of 2F5 and 4E10 epitopes. As shown
in Fig. 7, there was no significant difference in kinetics and
affinities of 2F5 and 4E10 for binding to NCM and NCM(TAIV).
Interestingly, however, the capacity of NCM(TAIV) captured into
Figure 7. Kinetic analysis of mAbs binding to NCM captured on membranes. (A) Sensorgrams obtained for 2F5 binding to NCM or
NCM(TAIV) captured on membranes. (B) Sensorgrams obtained for 4E10 binding to NCM or NCM(TAIV) captured on membranes. Experimental curves
(solid line) are shown overlaid with fitted curves (dash line) obtained with the 1:1 binding with drifting baseline model.
doi:10.1371/journal.pone.0018233.g007
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analogs with single mutation (Fig. 8), thus possibly explaining why
NCM(TAIV) has higher immunogenicity than NCM and other
NCM mutants.
Discussion
We and others have made extensive efforts and used different
strategies to induce neutralizing antibodies in vaccinated animals
using MPER-containing peptides, recombinant proteins or surface
antigen of human hepatitis B virus (HBV). Thus far, however, no
one has been able to elicit potent and broad neutralizing
antibodies, like 2F5 or 4E10, targeting the gp41 MPER region
[34,35,36,37,38,39,40,41,42]. This can be explained by the failure
of neutralizing epitopes in the MPER-based immunogens to
maintain the correct conformation. It is also possible that the gp41
NHR and CHR structures at the upstream of MEPR affect the
conformation and immunogenicity of neutralizing epitopes in
MPER. It follows that the immunogen should contain both MPER
and other regions in the gp41 ectodomain with appropriate
conformation.
In the present study, we used the gp41 ectodomain as the
basic structure to design the MPER-based immunogens. First,
we removed the fusion peptide (FP) from the immunogen since
our previous studies have shown that FP suppressed the
immunogenicity of MPER and that deleting FP resulted in
enhanced antigenicity and immunogenicity of the 4E10 epitope
[42]. Second, we replaced the immunodominant loop region
with an 8-mer (GGGKLGGG) linker, since the loop region
mainly elicits cluster I antibodies [43], which do not neutralize,
but rather enhance, HIV-1 infection [44]. The resulting
immunogen, contains the gp41 NHR, CHR and MPER
domains, thus designated NCM. Based on the crystal structure
of HR1-54Q, a similarly designed recombinant gp41 containing
MPER [45,46], NCM may also form 6HB core with an exposed
MPER tail since it reacted strongly with the 6HB-specific mAb
NC-1 [22] and the MPER-specific antibodies 2F5 and 4E10
[5,7,9,13,14] (Fig. 2). Finally, we introduced the T579A and/or
I675V mutations into NCM to generate three NCM mutants,
NCM(TA), NCM(IV) and NCM(TAIV) (Fig. 1A). It was
reported that introduction of T659A/I675V mutations into
gp41 of a neutralization-resistant HIV-1 variant significantly
increased exposure of the conserved neutralization epitopes in
MPER and resulted in 3- to 360-fold enhanced neutralization
by 2F5 and 4E10 [19]. Therefore, we assumed that introduc-
tion of the T659A and/or I675V mutations into NCM
might increase its immunogenicity for eliciting neutralizing
antibodies.
Indeed, as expected, all antisera from the rabbits immunized
with NCM(TAIV) had much higher titers of antibodies against the
gp41 MPER domain (1:16,127) than those from rabbits vaccinated
with NCM (1:504), NCM(TA) (1:1008) or NCM(IV) (1:1008)
(Table 1 and Fig. 3), suggesting that introducing both mutations
(T659A/I675V) could significantly enhance the immunogenicity
of the NCM-based immunogen.
There are two major antibody populations in the rabbit antisera
induced by NCM(TAIV) – the 6HB-specific and MPER-specific
antibodies. We purified these antibodies using affinity columns
conjugated with a recombinant 6HB protein and an MPER
peptide, respectively, and compared their neutralizing activities.
The 6HB-specific antibodies had no neutralizing activity at the
concentration of .150 mg/ml, while the MPER-specific antibod-
ies exhibited inhibitory activity against HIV-1 Env-mediated
syncytium-formation and infection by HIV-1 pseudoviruses,
laboratory-adapted and some primary HIV-1 isolates (Table 2).
These results indicate that the altered epitopes in the gp41 MPER,
rather than those in the gp41 6HB core, elicit neutralizing
antibodies in vaccinated animals.
The precise mechanism by which these mutations exposed
neutralization epitopes remained unclear, since chemical cross-
linking assay, together with antibodies binding assays by ELISA
and SPR, indicated no significant difference between NCM and
mutants. However, several studies have demonstrated that
strictly conserved T569 and I675 residues play important roles
in viral entry. T569 residue is located in the inner face of NHR
trimer and falls within the hydrophobic pocket which is critical
for interaction with CHR. Therefore, T569A mutation may
partially disrupt the gp41 6HB core conformation [19], resulting
in change of the overall conformation of gp41. It was reported
the I675V mutation could affect some physicochemical
properties of MPER which contribute to increased immunoge-
nicity. However, these changes could not fully explain the strong
immunogenicity of MPER in NCM(TAIV), since single-mutated
NCM(IV) did not elicit high titers of MPER-specific antibodies.
Therefore, we considered the effect of another interesting
finding that NCM(TAIV) showed lower capture level to
membranes. Many studies reported that the membrane plays
a crucial role in defining the structure of the MPER and,
consequently, the formation of the 2F5 and 4E10 epitopes. The
long CDR-H3s of these antibodies were involved in the
Figure 8. Capture levels of NCMs binding to membrane. (A)
Sensorgrams obtained for 1 mM NCMs binding to POPC/Chol/SM
membranes on the L1 sensor chips. (B) Different capture levels of
NCMs (RUs at 400s post-injection).
doi:10.1371/journal.pone.0018233.g008
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MPER in membrane may have a negative effect on immuno-
genicity of MPER because of the steric restrictions imposed by
the viral membrane which may hamper the generation of
antibodies. Although the rabbits were immunized with NCM
and its mutants in the absence of liposomes, the immunogen
could diffuse and nonspecifically interact with membrane
systems in multiple immune processes after subcutaneous
injections. This interaction may result in the decreased exposure
of the epitopes on MPER, rendering a correspondingly poorer
immunogenicity. On the contrary, decreasing the immersion
depth of epitopes in membrane could contribute to an increase
of immunogenicity. In fact, the 4E10 epitope was immersed in
the polar/apolar interfacial region of the lipid bilayer, whereas
2F5 epitope was more solvent exposable [49]. Thus the
exposure of 4E10 epitope might be more sensitive to immersion
depth. I675 residue was reported to be one of the rare residues
which immersed deeply both before and after 4E10 binding
[10]. Therefore, a shorter side chain of Valine in I675V mutant
may facilitate the decreasing immersion depth of MPER,
especially the 4E10 epitope. Still, how T569A and I675V
mutations synergistically affect the capture level of NCM(TAIV)
remains to be further studied. We suggested that the moderate
immersion depth of MPER in membranes, which made MPER
more exposed, but antigenically preserved, was another reason
underlying the ability of NCM(TAIV) to elicit higher titers of
MPER-specific antibodies. Interestingly, the induced MPER-
specific antibodies mainly targeted an extended 4E10 epitope as
we had expected. Thus, physicochemical property and structure
changes, together with decreased immersion depth, may
correlate with the increased immunogenicity of MPER in
NCM(TAIV).
Although NCM(TAIV) could elicit relatively higher titers of
MPER-specific antibodies than non-mutated NCM or other gp41-
derived recombinant proteins described previously, it lacks the
ability to induce highly potent and broad neutralizing antibodies
against primary HIV-1 isolates. Therefore, more efforts should be
taken to make NCM(TAIV) a rational candidate for an HIV
vaccine to elicit higher titer and more potent and broader
neutralizing antibodies. Fortunately, many studies have provided
some useful suggestions, such as implementing a new immuniza-
tion strategy [15], using strong adjuvants to break B-cell tolerance
[50], or introducing mutations which could favor the formation of
prehairpin intermediate conformation or prolong exposure of
MPER [51,52].
In conclusion, our study presented a rationally designed
immunogen consisting of the gp41 6HB core and the exposed
MPER tail with a double mutation (T569A and I675V). This
immunogen could elicit high titers of MPER-specific antibodies
with broad neutralizing activity. Although the precise underlying
molecular mechanism remained unclear, we confirmed that that
double T569A/I675V mutations in gp41 are critical for
significantly enhancing the immunogenicity of neutralizing
epitopes in the gp41 MPER. Therefore, this study might provide
important implications for designing novel MPER-based HIV-1
vaccines with increased immunogenicity for eliciting potent and
broad neutralizing antibodies.
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